Journal of Medical Molecular Biology ›› 2025, Vol. 22 ›› Issue (5): 500-507.doi: 10.3870/j.issn.1672-8009.2025.05.013

Previous Articles     Next Articles

Research Progress of Fruquintinib in Colorectal Cancer #br#

  

  1. 1The Second Clinical School, Wuhan University, Wuhan, 430071, China 2Department of Gastrointestinal Surgery,3Hubei Key Laboratory of Tumor Biological Behaviors,4Hubei Cancer Clinical Study Center,5The Clinical Medical Research Center of Peritoneal Cancer of Wuhan, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China
  • Online:2025-09-30 Published:2025-10-09

PDF (PC)

5

Abstract: Fruquintinib is a novel and highly selective inhibitor of vascular endothelial growthfactor receptor (VEGFR), which plays an important role in the comprehensive treatment of colorectal cancer (CRC). Numerous studies have shown that fruquintinib can effectively block tumor angiogenesis and has demonstrated significant efficacy and good tolerance in the treatment of metastatic CRC. This review aims to summarize and discuss the pharmacological mechanism, pharmacokinetic characteristics, adverse event of fruquintinib, as well as the results of a series of clinical trials in CRC. Additionally, this review explores the potential of combining VEGFR inhibitors with other therapies, providing new directions for further optimizing its use in personalized treatment.

Key words:

fruquintinib, colorectal cancer, vascular endothelial growth factor, clinical trial, adverse event

CLC Number: